Bleeding in acquired hemophilia: have we fi gured it out?
Open Access
- 16 July 2020
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 136 (3), 262-264
- https://doi.org/10.1182/blood.2020006098
Abstract
In this issue of Blood , Holstein et al show the extent to which the risk of bleeding after a diagnosis of acquired hemophilia A (AHA) remains significant until near -normal factor VIII (FVIII) level is attained.(1)This publication has 10 references indexed in Scilit:
- Bleeding and Response to Hemostatic Therapy in Acquired Hemophilia A (AHA): Results from the GTH-AH 01/2010 StudyBlood, 2020
- New therapies using nonfactor products for patients with hemophilia and inhibitorsBlood, 2019
- Relapse pattern and long‐term outcomes in subjects with acquired haemophilia AHaemophilia, 2019
- Acquired hemophilia A: Updated review of evidence and treatment guidanceAmerican Journal of Hematology, 2017
- Anti–factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 studyBlood, 2016
- The influence of corticosteroids on hemostasis in healthy subjectsJournal of Thrombosis and Haemostasis, 2016
- Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 studyBlood, 2015
- Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)Journal of Thrombosis and Haemostasis, 2012
- International recommendations on the diagnosis and treatment of patients with acquired hemophilia AHaematologica, 2009
- Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' OrganisationBlood, 2006